Carregant...
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma
Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype. Preliminary evidence suggests tha...
Guardat en:
| Publicat a: | Leuk Lymphoma |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5918224/ https://ncbi.nlm.nih.gov/pubmed/29065744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1390230 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|